Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans

ISSN: 2212-3989 (Online)
ISSN: 1871-5265 (Print)


Volume 14, 3 Issues, 2014


Download PDF Flyer




Infectious Disorders - Drug Targets

Formerly: Current Drug Targets - Infectious Disorders

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Jean-Marc Sabatier
Laboratoire ERT 62 'Ingénierie des peptides à visée thérapeutique'
Université de la Méditerranée
Faculté de Médecine Nord
Boulevard Pierre Dramard
13916 - MARSEILLE, Cedex 20
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans

Author(s): David R. Strayer, Robert Dickey and William A. Carter

Affiliation: Hemispherx Biopharma, Inc., Philadelphia, PA 19103, USA.

Abstract

A novel coronavirus (MERS-CoV) related to SARS-CoV recently emerged in the Middle East causing more than 400 deaths with a mortality rate of about 30%, much higher than SARS-CoV. Both viruses target epithelial cells in the respiratory tract, although utilizing different cellular receptors. Because of the sporadic nature of the MERS outbreak and difficulty in collecting randomized, controlled clinical data, the objective of this review was to focus on published in vitro and in vivo drug sensitivity data using both cell lines and available animal models of SARS/MERS CoV infection. Determination of drug activity was based on achievable serum levels in humans relative to in vitro IC50 (50% inhibitory concentration) or EC50 (50% effective concentration) drug concentrations. The most active drugs against SARS/MERS CoV at clinically achievable serum levels were type I interferons and a TLR3 agonist, interferon inducer/activator.

Keywords: Antivirals, Cmax, coronaviruses, EC50, IC50, interferons, MERS, SARS.

Download Free Rights and Permissions

  
  



Article Details

Volume: 14
Issue Number: 1
First Page: 37
Last Page: 43
Page Count: 7
DOI: 10.2174/1871526514666140713152858
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science